A series of studies indicated that MCL-1 is over-expressed in many cancer types (multiple myeloma, lymphomas, leukaemia) and therefore it is widely recognised as a druggable target (Albershardt et al., 2011). This evidence concerns the gene MCL1 and lymphoma.